tiprankstipranks
Trending News
More News >
BridgeBio Oncology Therapeutics (BBOT)
NASDAQ:BBOT
US Market

BridgeBio Oncology Therapeutics (BBOT) Income Statement

Compare
21 Followers

BridgeBio Oncology Therapeutics Income Statement

Last quarter (Q3 2025), BridgeBio Oncology Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, BridgeBio Oncology Therapeutics's net income was $-44.76M. See BridgeBio Oncology Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 80.86M$ 64.77M$ 3.52K$ 43.36K$ -90.84K
Depreciation and Amortization
$ 208.00K$ 92.00K$ 0.00$ 0.00$ 206.30K
EBITDA
$ -80.66M$ -64.68M$ -3.52K$ -43.36K$ -90.84K
Operating Income
$ -80.86M$ -64.77M$ 0.00$ -43.36K$ -90.84K
Other Income/Expenses
$ 6.59M$ 72.00K$ 0.00$ 0.00$ 0.00
Pretax Income
$ -74.28M$ -64.70M$ -3.52K$ -43.36K$ -90.84K
Net Income
$ -74.28M$ -64.70M$ -3.52K$ -43.36K$ -90.84K
Per Share Metrics
Basic EPS
$ 0.46$ 0.00$ 0.00$ 0.00$ -0.01
Diluted EPS
$ 0.46$ 0.00$ 0.00$ 0.00$ -0.01
Weighted Average Shares Outstanding
16.64M 20.48M 20.48M 20.48M 14.81M
Weighted Average Shares Outstanding (Diluted)
16.64M 20.48M 20.48M 20.48M 14.81M
Currency in USD

BridgeBio Oncology Therapeutics Earnings and Revenue History